Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2510 + IMM27M in advanced solid tumors
NCT06764836Phase 1Recruiting
- Sponsor
- ImmuneOnco
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Prophylactic Vaccines, IgG Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM2510 and IMM27M in solid tumor, triple-negative breast cancer (TNBC) and hepatocellular carcinoma (HCC), sponsored by ImmuneOnco. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
IMM2510IMM27M
03
Conditions
solid tumortriple-negative breast cancer (TNBC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06764836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764836.